BR0209074A - Derivados de octreotìdeos glicosilados radioativos marcadores com tc e re - Google Patents
Derivados de octreotìdeos glicosilados radioativos marcadores com tc e reInfo
- Publication number
- BR0209074A BR0209074A BR0209074-0A BR0209074A BR0209074A BR 0209074 A BR0209074 A BR 0209074A BR 0209074 A BR0209074 A BR 0209074A BR 0209074 A BR0209074 A BR 0209074A
- Authority
- BR
- Brazil
- Prior art keywords
- ligands
- peptide
- sst
- group
- radioactive
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title abstract 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical class C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001720 carbohydrates Chemical group 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
- 102000011096 Somatostatin receptor Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
"DERIVADOS DE OCTREOTìDEOS GLICOSILADOS RADIOATIVOS MARCADORES COM Tc E Re". A presente invenção refere-se a ligandos peptídicos melhorados que se aglutinam a receptores sst para aplicações de diagnósticos e terapêuticas na medicina nuclear. Os ligandos melhorados contêm aminoácidos naturais ou não naturais ou estruturas peptideo miméticas que são modificadas na extremidade N-terminal ou C-terminal ou em ambos os terminais, uma unidade de carboidrato e um quelante ou grupo prostético para fornecer uma complexação de um radioisótopo que se liga ou que sustenta o radioisótopo. Os ligandos peptídicos que se ligam ao receptor sst ou SSTR podem conter ainda uma ou mais unidades ligantes multifuncionais que acoplam opcionalmente o peptídeo e/ou o grupamento de açúcar e/ou o quelante e/ou o grupo prostético. Após a administração do ligando a um mamífero através do sistema sang³íneo o ligando fornece maior disponibilidade, cinética de eliminação, direcionamento e internalização do receptor sst sobre os ligandos que não são carboidratados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01201466 | 2001-04-23 | ||
PCT/US2002/012565 WO2002085418A2 (en) | 2001-04-23 | 2002-04-23 | Tc and re labeler radioactive glycosylated octreotide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209074A true BR0209074A (pt) | 2004-08-10 |
Family
ID=8180193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209074-0A BR0209074A (pt) | 2001-04-23 | 2002-04-23 | Derivados de octreotìdeos glicosilados radioativos marcadores com tc e re |
Country Status (11)
Country | Link |
---|---|
US (2) | US7589061B2 (pt) |
EP (1) | EP1381396B1 (pt) |
JP (3) | JP5398945B2 (pt) |
AT (1) | ATE427125T1 (pt) |
AU (1) | AU2002254691B8 (pt) |
BR (1) | BR0209074A (pt) |
CA (1) | CA2443273C (pt) |
CZ (1) | CZ20032872A3 (pt) |
DE (1) | DE60231801D1 (pt) |
HU (1) | HU228811B1 (pt) |
WO (1) | WO2002085418A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7956165B2 (en) | 2003-07-24 | 2011-06-07 | Affisink Biotechnology Ltd. | Compositions and methods for purifying and crystallizing molecules of interest |
IL157086A0 (en) * | 2003-07-24 | 2004-02-08 | Guy Patchornik | Multivalent ligand complexes |
CN102253174A (zh) * | 2011-04-27 | 2011-11-23 | 江苏省原子医学研究所 | 一种受体显像剂标记的化学动力学研究的方法 |
WO2013032012A1 (ja) * | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
RU2624034C2 (ru) | 2011-09-04 | 2017-06-30 | Глитек, Инк. | Гликозилированные полипептиды и лекарственные композиции, содержащие данные полипептиды |
AU2014396468B2 (en) * | 2014-06-06 | 2019-02-21 | Technische Universitat Munchen | Modified cyclopentapeptides and uses thereof |
JP7084417B2 (ja) | 2017-01-12 | 2022-06-14 | ラジオメディックス インコーポレイテッド | 放射性同位体にキレートされたオクトレオチド誘導体を用いるソマトスタチン受容体を過剰発現しているがん細胞の治療 |
BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU906340D0 (en) * | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
JP2544159B2 (ja) | 1987-10-07 | 1996-10-16 | ハウス食品株式会社 | 連続蒸煮装置 |
MY106120A (en) | 1988-12-05 | 1995-03-31 | Novartis Ag | Peptide derivatives. |
US5590656A (en) * | 1992-09-15 | 1997-01-07 | The Ohio State University Research Foundation | Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue |
US5968477A (en) | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
JPH10512852A (ja) | 1994-12-07 | 1998-12-08 | ネオルクス コーポレイション | 放射性標識化アネキシン−ガラクトースクラスター複合体 |
CA2206274C (en) | 1994-12-07 | 2009-06-30 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
US5753206A (en) * | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
EP0888381A4 (en) | 1995-12-21 | 2001-10-17 | Scripps Research Inst | TARGETED THERAPEUTIC AND DIAGNOSTIC AGENTS, METHODS FOR THEIR PRODUCTION AND USE |
DE19654764A1 (de) | 1996-12-30 | 1998-07-02 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung eines Peptidgemisches |
EA200001007A1 (ru) | 1998-03-31 | 2001-04-23 | Дюпон Фармасьютикалз Компани | Фармацевтические препараты для визуализации ангиогенных расстройств |
DE19910419A1 (de) | 1999-03-10 | 2000-09-21 | Aventis Pharma Gmbh | Zielzellspezifische, multivalente Proteine (MVP) |
-
2002
- 2002-04-23 CA CA2443273A patent/CA2443273C/en not_active Expired - Fee Related
- 2002-04-23 HU HU0303987A patent/HU228811B1/hu not_active IP Right Cessation
- 2002-04-23 CZ CZ20032872A patent/CZ20032872A3/cs unknown
- 2002-04-23 AU AU2002254691A patent/AU2002254691B8/en not_active Ceased
- 2002-04-23 JP JP2002582991A patent/JP5398945B2/ja not_active Expired - Fee Related
- 2002-04-23 AT AT02723932T patent/ATE427125T1/de not_active IP Right Cessation
- 2002-04-23 BR BR0209074-0A patent/BR0209074A/pt not_active IP Right Cessation
- 2002-04-23 DE DE60231801T patent/DE60231801D1/de not_active Expired - Lifetime
- 2002-04-23 US US10/475,696 patent/US7589061B2/en not_active Expired - Fee Related
- 2002-04-23 WO PCT/US2002/012565 patent/WO2002085418A2/en active IP Right Grant
- 2002-04-23 EP EP02723932A patent/EP1381396B1/en not_active Expired - Lifetime
-
2009
- 2009-09-10 US US12/556,698 patent/US8575100B2/en not_active Expired - Fee Related
- 2009-09-30 JP JP2009228998A patent/JP2010001313A/ja not_active Withdrawn
-
2013
- 2013-02-08 JP JP2013023001A patent/JP2013100349A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2002085418A3 (en) | 2003-09-12 |
CA2443273C (en) | 2011-09-27 |
HUP0303987A3 (en) | 2010-03-29 |
HU228811B1 (hu) | 2013-05-28 |
JP5398945B2 (ja) | 2014-01-29 |
HUP0303987A2 (hu) | 2004-03-01 |
JP2005514321A (ja) | 2005-05-19 |
EP1381396A2 (en) | 2004-01-21 |
US20090324497A1 (en) | 2009-12-31 |
ATE427125T1 (de) | 2009-04-15 |
EP1381396B1 (en) | 2009-04-01 |
JP2010001313A (ja) | 2010-01-07 |
CZ20032872A3 (cs) | 2005-01-12 |
CA2443273A1 (en) | 2002-10-31 |
AU2002254691B2 (en) | 2007-06-14 |
JP2013100349A (ja) | 2013-05-23 |
US20060165593A1 (en) | 2006-07-27 |
DE60231801D1 (de) | 2009-05-14 |
US8575100B2 (en) | 2013-11-05 |
US7589061B2 (en) | 2009-09-15 |
WO2002085418A2 (en) | 2002-10-31 |
AU2002254691B8 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Béhé et al. | Cholecystokinin‐B (CCK‐B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK‐B receptor expressing malignancies | |
Hoffman et al. | Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells | |
Kumagai et al. | Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. | |
EP0630265B1 (en) | TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION | |
FI117424B (fi) | Peptidejä | |
WO1999000150A2 (en) | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor | |
WO1989010134A1 (en) | Chimeric peptides for neuropeptide delivery through the blood-brain barrier | |
Lin et al. | Effects of chelator modifications on 68 Ga-labeled [Tyr 3] octreotide conjugates | |
JP2008517917A (ja) | 癌を治療するための毒素および放射性核種結合igf−1受容体リガンド | |
Tolmachev et al. | Targeted nuclear medicine. Seek and destroy | |
BR0209074A (pt) | Derivados de octreotìdeos glicosilados radioativos marcadores com tc e re | |
Tran et al. | Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging | |
US5082928A (en) | Method of preparing conjugated antibodies | |
Tolmachev et al. | Closo-dodecaborate (2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution | |
WO2022112323A1 (en) | Stable formulations for radionuclide complexes | |
Zoghi et al. | Development of a 68 Ga-peptide tracer for PET GnRH1-imaging | |
Verbeke et al. | Technetium-99m mercaptoalbumin as a potential substitute for technetium-99m labelled red blood cells | |
Trachsel et al. | Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK | |
AU2002254691A1 (en) | Tc and Re labeler radioactive glycosylated octreotide derivatives | |
Aloj et al. | Radiolabeling approaches for cholecystokinin B receptor imaging | |
US5208008A (en) | Regioselective chemical modification of monoclonal antibodies | |
Ramjeesingh et al. | Antigen protection of monoclonal antibodies undergoing labelling | |
Blok et al. | Monoclonal Antibodies in Radioimmunoscintigraphy Some hurdles between clone and clinic | |
JPH05501107A (ja) | 画像用放射標識抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: MALLINCKRODT LLC (US) Free format text: NOME ALTERADO DE: MALLINCKRODT INC. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |